My site

BASEL, Switzerland - Friday, 09. September 2022

Tenalisib (RP6530, selective dual PI3K d/γ inhibitor with additional SIK3 inhibitory activity) showed encouraging results with a clinical benefit rate (CBR) of 57.5% from an ongoing phase II trial in patients with locally advanced or metastatic HR+/HER2- breast cancer (mBC)
RP12146, Rhizen’s next generation PARP1/2 inhibitor concludes dose escalation phase with a favorable safety profile and has moved to the dose expansion phase in solid tumors
 

(BUSINESS WIRE) -- Rhizen Pharmaceuticals AG (Rhizen), a Swiss based privately held, clinical-stage biopharmaceutical company announced today that it is presenting data from an ongoing Phase 2 trial of Tenalisib in locally advanced or metastatic breast cancer and data from a concluded dose escalation phase of RP12146 at ESMO 2022, Paris from Sept 9-13, 2022.

The multi-centre, randomized phase II study evaluating two doses of Tenalisib, a dif ... Read more »

Rimini Street is now globally recognized by its employees for building an inclusive, high trust, high-performance culture with career growth and development opportunities for all employees

(BUSINESS WIRE)--Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products, and a Salesforce partner, today announced that Rimini Street has earned the designation of Great Place to Work-Certified™ in Australia, New Zealand, and the US. Last year, Rimini Street was certified in India, Korea, and the UK.

Great Place to Work is an internationally recognized benchmark certification for organizations that go above and beyond to provide an exceptional employee experience. The certification is achieved by distributing a third-party survey which has to be completed each year for re-certification. The survey is sent to employees in a geographic area to measure emplo ... Read more »

Syntagma Capital Enters Into Exclusive Negotiations to Carve out a Significant Part of Imerys’ Business Serving the Paper Markets for an Enterprise Value of €390m

BRUSSELS - Friday, 09. September 2022